{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:09:17Z","timestamp":1795140557525,"version":"4.10.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hellenic Institute for the Study of Sepsis Swedish Orphan BioVitrum AB","id":[{"id":"https:\/\/ror.org\/02n4vr545","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1\u03b1\/\u03b2 inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR \u22656\u2009ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    , 85.9% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009510) of whom were receiving dexamethasone. At day 28, the adjusted proportional odds of having a worse clinical status (assessed by the 11-point World Health Organization Clinical Progression Scale (WHO-CPS)) with anakinra, as compared to placebo, was 0.36 (95%\u2009confidence interval 0.26\u20130.50). The median WHO-CPS decrease on day 28 from baseline in the placebo and anakinra groups was 3 and 4 points, respectively (odds ratio (OR) = 0.40,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001); the respective median decrease of Sequential Organ Failure Assessment (SOFA) score on day 7 from baseline was 0 and 1 points (OR = 0.63,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.045), and hospital stay was shorter.\n                  <\/jats:p>","DOI":"10.1038\/s41591-021-01499-z","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:22:07Z","timestamp":1630657327000},"page":"1752-1760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":503,"title":["Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-517X","authenticated-orcid":false,"given":"Evdoxia","family":"Kyriazopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyfallia","family":"Poulakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Metallidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Adamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-905X","authenticated-orcid":false,"given":"Konstantinos","family":"Tsiakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archontoula","family":"Fragkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggeliki","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Damoulari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6913-8460","authenticated-orcid":false,"given":"Massimo","family":"Fantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9729-3492","authenticated-orcid":false,"given":"Ioannis","family":"Kalomenidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Chrysos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-8034","authenticated-orcid":false,"given":"Andrea","family":"Angheben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Kainis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Saverio","family":"Serino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tsilika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Bakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Tzavara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Kostis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-3306","authenticated-orcid":false,"given":"Panagiotis","family":"Koufargyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Dimakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Savvanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glykeria","family":"Tzatzagou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Katrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tsoukalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Bliziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-9712","authenticated-orcid":false,"given":"Michael","family":"Samarkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ktena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Masgala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-2925","authenticated-orcid":false,"given":"Ilias","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-9435","authenticated-orcid":false,"given":"Maria","family":"Kosmidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra-Melia","family":"Myrodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Argyraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Simona","family":"Cardellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Koliakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni-Ioanna","family":"Katsigianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymia","family":"Giannitsioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cingolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Micha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-920X","authenticated-orcid":false,"given":"Orestis","family":"Liatsis-Douvitsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Symbardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mouktaroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-2979","authenticated-orcid":false,"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-099X","authenticated-orcid":false,"given":"Eleni","family":"Florou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antigone","family":"Kotsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-6052","authenticated-orcid":false,"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-4275","authenticated-orcid":false,"given":"Jesper","family":"Eugen-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-1789","authenticated-orcid":false,"given":"Miltiades","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"1499_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02897-4","volume":"24","author":"N Rovina","year":"2020","unstructured":"Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care 24, 187 (2020).","journal-title":"Crit. Care"},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1681\/ASN.2020060829","volume":"31","author":"TU Azam","year":"2021","unstructured":"Azam, T. U. et al. Soluble urokinase receptor (suPAR) in COVID-19-related AKI. J. Am. Soc. Nephrol. 31, 2725\u20132735 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1499_CR3","doi-asserted-by":"publisher","unstructured":"Renieris, G. et al. IL-1 mediates tissue specific inflammation and severe respiratory failure in Covid-19: clinical and experimental evidence. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.04.09.21255190 (2021).","DOI":"10.1101\/2021.04.09.21255190"},{"key":"1499_CR4","doi-asserted-by":"publisher","first-page":"e20201707","DOI":"10.1084\/jem.20201707","volume":"218","author":"TS Rodrigues","year":"2021","unstructured":"Rodrigues, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 218, e20201707 (2021).","journal-title":"J. Exp. Med."},{"key":"1499_CR5","doi-asserted-by":"publisher","first-page":"e66125","DOI":"10.7554\/eLife.66125","volume":"10","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou, E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10, e66125 (2021).","journal-title":"eLife"},{"key":"1499_CR6","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(20)30275-7","volume":"2","author":"JJ Manson","year":"2020","unstructured":"Manson, J. J. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2, e594\u2013e602 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1499_CR7","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","volume":"2","author":"BJ Webb","year":"2020","unstructured":"Webb, B. J. et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2, e754\u2013e763 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1499_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2020-218323","volume":"80","author":"R Caricchio","year":"2021","unstructured":"Caricchio, R. et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann. Rheum. Dis. 80, 88\u201395 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1499_CR9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645 (2021).","journal-title":"Lancet"},{"key":"1499_CR10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1499_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 385, 406\u2013415 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1499_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jama.2021.9508","volume":"236","author":"R Caricchio","year":"2021","unstructured":"Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive ventilation in patients hospitalized with severe COVID-19. A randomized clinical trial. JAMA 236, 230\u2013239 (2021).","journal-title":"JAMA"},{"key":"1499_CR13","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","volume":"19","author":"Y Jamilloux","year":"2020","unstructured":"Jamilloux, Y. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun. Rev. 19, 102567 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1499_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","volume":"147","author":"G Bozzi","year":"2021","unstructured":"Bozzi, G. et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J. Allergy Clin. Immunol. 147, 561\u2013566 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","volume":"3","author":"G Cavalli","year":"2021","unstructured":"Cavalli, G. et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 3, e253\u2013e261 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1499_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03364-w","volume":"24","author":"EJ Kooistra","year":"2020","unstructured":"Kooistra, E. J. et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit. Care 24, 688 (2020).","journal-title":"Crit. Care"},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"18951","DOI":"10.1073\/pnas.2009017117","volume":"117","author":"R Cauchois","year":"2020","unstructured":"Cauchois, R. et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc. Natl Acad. Sci. USA 117, 18951\u201318953 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","volume":"147","author":"E Pontali","year":"2021","unstructured":"Pontali, E. et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J. Allergy Clin. Immunol. 147, 1217\u20131225 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","volume":"2","author":"T Huet","year":"2020","unstructured":"Huet, T. et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2, e393\u2013e400 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1499_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","volume":"9","author":"CORIMUNO-19 Collaborative Group.","year":"2021","unstructured":"CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med. 9, 295\u2013304 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1499_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","volume":"103","author":"A Balkhair","year":"2021","unstructured":"Balkhair, A. et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int. J. Infect. Dis. 103, 288\u2013296 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 384, 1503\u20131516 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1499_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384, 20\u201330 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1499_CR24","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 383, 2333\u20132344 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1499_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","volume":"181","author":"C Salvarani","year":"2021","unstructured":"Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern. Med. 181, 24\u201331 (2021).","journal-title":"JAMA Intern. Med."},{"key":"1499_CR26","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992\u20131000 (2020).","journal-title":"Cell Host Microbe"}],"updated-by":[{"DOI":"10.1038\/s41591-021-01569-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01499-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T11:29:58Z","timestamp":1634210998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01499-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01499-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.16.21257283","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-646951\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"22 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-021-01569-2","URL":"https:\/\/doi.org\/10.1038\/s41591-021-01569-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.P. has received independent educational grants from Pfizer, MSD, Angelini and Bio-Rad. H.M. reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer and Servier. L.D. received consultation honoraria from Sobi. M.B. has received funds for research grants and\/or advisor\/consultant and\/or speaker\/chairman from Angelini, Astellas, Bayer, bioM\u00e9rieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Roche, Shionogi and Nabriva. M.G.N. is supported by an ERC Advanced Grant (no. 833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. He has also received independent educational grants from TTxD, GSK and ViiV Healthcare. J.E.-O. is a co-founder, shareholder and CSO of ViroGates, Denmark, and is a named inventor on patients on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. P.P. has received honoraria from Gilead, Janssen and MSD. G.N.D. is an advisor or lecturer for Ipsen, Pfizer, Genkyotex, Novartis and Sobi, has received research grants from Abbvie and Gilead and has served as principal investigator in studies for Abbvie, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics, Sobi and Intercept Pharmaceuticals. E.J.G.-B. has received honoraria from Abbott, bioM\u00e9rieux, Brahms, GSK, InflaRx, Sobi and XBiotech; independent educational grants from Abbott, AxisShield, bioM\u00e9rieux, InflaRx, Johnson & Johnson, MSD, Sobi and XBiotech; and funding from the Horizon 2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens) and the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not have any competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}